vs
Side-by-side financial comparison of MEDIFAST INC (MED) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $60.1M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs -36.9%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs -34.4%).
Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
MED vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $60.1M |
| Net Profit | — | $-55.6M |
| Gross Margin | 69.4% | 88.1% |
| Operating Margin | -10.4% | -87.1% |
| Net Margin | — | -92.6% |
| Revenue YoY | -36.9% | 83.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-1.64 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | $75.1M | $57.3M | ||
| Q3 25 | $89.4M | $51.3M | ||
| Q2 25 | $105.6M | $48.5M | ||
| Q1 25 | $115.7M | $32.7M | ||
| Q4 24 | $119.0M | $41.8M | ||
| Q3 24 | $140.2M | $33.3M | ||
| Q2 24 | $168.6M | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $-2.3M | $-52.9M | ||
| Q2 25 | $2.5M | $-46.6M | ||
| Q1 25 | $-772.0K | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $1.1M | $-43.6M | ||
| Q2 24 | $-8.2M | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | 69.4% | 91.6% | ||
| Q3 25 | 69.5% | 89.3% | ||
| Q2 25 | 72.6% | 88.6% | ||
| Q1 25 | 72.8% | 88.8% | ||
| Q4 24 | 74.1% | 90.9% | ||
| Q3 24 | 75.4% | 88.5% | ||
| Q2 24 | 73.2% | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | -10.4% | -82.2% | ||
| Q3 25 | -4.6% | -102.6% | ||
| Q2 25 | -1.0% | -93.4% | ||
| Q1 25 | -1.1% | -143.7% | ||
| Q4 24 | 0.6% | -98.6% | ||
| Q3 24 | 1.5% | -132.0% | ||
| Q2 24 | -4.7% | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | -2.5% | -103.1% | ||
| Q2 25 | 2.3% | -96.1% | ||
| Q1 25 | -0.7% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | 0.8% | -131.2% | ||
| Q2 24 | -4.8% | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $-1.64 | $-0.73 | ||
| Q3 25 | $-0.21 | $-0.82 | ||
| Q2 25 | $0.22 | $-0.75 | ||
| Q1 25 | $-0.07 | $-0.81 | ||
| Q4 24 | $0.08 | $-0.71 | ||
| Q3 24 | $0.10 | $-0.73 | ||
| Q2 24 | $-0.75 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.3M | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $198.9M | $122.9M |
| Total Assets | $248.0M | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | $167.3M | $388.9M | ||
| Q3 25 | $173.5M | $416.1M | ||
| Q2 25 | $162.7M | $291.0M | ||
| Q1 25 | $164.6M | $314.5M | ||
| Q4 24 | $162.3M | $320.6M | ||
| Q3 24 | $170.0M | $298.4M | ||
| Q2 24 | $163.5M | $319.1M |
| Q1 26 | — | $122.9M | ||
| Q4 25 | $198.9M | $139.1M | ||
| Q3 25 | $214.7M | $148.8M | ||
| Q2 25 | $216.0M | $-11.9M | ||
| Q1 25 | $211.0M | $18.9M | ||
| Q4 24 | $210.1M | $21.7M | ||
| Q3 24 | $207.3M | $11.2M | ||
| Q2 24 | $205.3M | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | $248.0M | $480.2M | ||
| Q3 25 | $268.2M | $506.9M | ||
| Q2 25 | $269.3M | $372.7M | ||
| Q1 25 | $280.0M | $386.7M | ||
| Q4 24 | $284.2M | $392.3M | ||
| Q3 24 | $291.2M | $363.6M | ||
| Q2 24 | $293.5M | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.3M | — |
| Free Cash FlowOCF − Capex | $-6.6M | — |
| FCF MarginFCF / Revenue | -8.8% | — |
| Capex IntensityCapex / Revenue | 1.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-5.3M | $-25.4M | ||
| Q3 25 | $12.1M | $-26.6M | ||
| Q2 25 | $-3.4M | $-23.3M | ||
| Q1 25 | $3.4M | $-40.4M | ||
| Q4 24 | $-4.9M | $-18.8M | ||
| Q3 24 | $9.1M | $-25.2M | ||
| Q2 24 | $13.1M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-6.6M | — | ||
| Q3 25 | $10.8M | — | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $-7.2M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $11.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | -8.8% | — | ||
| Q3 25 | 12.0% | — | ||
| Q2 25 | -4.5% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | -6.1% | — | ||
| Q3 24 | 5.5% | — | ||
| Q2 24 | 6.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 1.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.36× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.04× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
